Loading
Cancer Survivorship and Care · Journal article
Healthcare · September 10, 2026
Encouraging direction, but not yet definitive.
This prospective randomized pilot study compared non-ablative Er:YAG laser therapy with hyaluronic acid gel for genitourinary syndrome of menopause in women with hormone-dependent cancer. The primary endpoint (total VSQ change) showed no significant between-group difference, but an exploratory baseline-adjusted analysis of total FSFI favored laser therapy by 2.72 points. Within-group improvements occurred under both interventions, but the absence of a control arm prevents attribution of benefit to the active treatments alone.
Prospective randomized active-comparator pilot study. Women with hormone-dependent malignancies and genitourinary syndrome of menopause; specific eligibility criteria and setting not detailed in abstract. Intervention: Non-ablative Er:YAG vaginal laser therapy (three sessions). Compared with: 0.2% hyaluronic acid vaginal gel applied intravaginally every 72 hours for two months. n = 65.
Primary endpoint (total VSQ change): no significant between-group difference (p = 0.398) Total FSFI change favored laser therapy in unadjusted analysis (p = 0.034) with adjusted difference of 2.72 points (95% CI, 0.19–5.25; p = 0.036) Within-group improvements observed under both interventions
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest a possible benefit of laser therapy over gel for sexual function, but the result is from a small pilot without a control arm and requires confirmation in larger controlled trials. The comparable vulvovaginal symptom improvement between treatments suggests both may offer benefit, though causation cannot be established without an untreated control.
A small randomized pilot comparing two active treatments in a vulnerable population with patient-reported outcomes, showing within-group improvement and a modest between-group difference on one secondary endpoint that requires confirmation.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest a possible benefit of laser therapy over gel for sexual function, but the result is from a small pilot without a control arm and requires confirmation in larger controlled trials. The comparable vulvovaginal symptom improvement between treatments suggests both may offer benefit, though causation cannot be established without an untreated control.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Genitourinary syndrome of menopause (GSM) is a common consequence of hypoestrogenism that negatively affects vulvovaginal health, sexual function, and quality of life. Evidence comparing non-hormonal treatment options in women with hormone-dependent malignancies remains limited. This study evaluated patient-reported outcomes following non-ablative Er:YAG laser therapy or hyaluronic acid vaginal gel in women with hormone-dependent cancer and GSM. Methods: In this prospective randomized pilot study, 65 women with hormone-dependent malignancies and GSM were randomized to receive either three sessions of non-ablative Er:YAG vaginal laser therapy (n = 34) or 0.2% hyaluronic acid vaginal gel applied intravaginally every 72 h for two months (n = 31). The primary outcome was change in the total Vulvovaginal Symptom Questionnaire (VSQ) score; change in the total Female Sexual Function Index (FSFI) score was a secondary outcome, and domain-level analyses were exploratory. Outcomes were assessed at baseline and one month after treatment. Wilcoxon signed-rank and Mann–Whitney U tests were used for the principal analyses; adjusted analyses were performed using ANCOVA. The study was retrospectively registered at ClinicalTrials.gov (Identifier: NCT07420647; first posted on 19 February 2026). Results: Within-group improvements were observed under both active interventions. The primary between-group comparison showed no difference in total VSQ change (p = 0.398). Total FSFI change favored laser therapy in the unadjusted between-group comparison (p = 0.034), and the exploratory baseline-adjusted difference was 2.72 points (95% CI, 0.19–5.25; p = 0.036). Domain-level analyses were exploratory and were not adjusted for multiplicity. Conclusions: In this active-comparator pilot study, total VSQ change was comparable between groups and the adjusted total FSFI estimate favored laser therapy. Without a sham or untreated control, within-group changes cannot establish intervention-specific efficacy; these comparative findings require confirmation in larger controlled trials.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.